Approved for use against rheumatoid arthritis drug Kovid-19

According to the news of the public broadcaster NHK, the rheumatoid arthritis drug “Baricitinib”, a drug produced by Eli Lily from the USA, applied in December 2020, was approved by the ministry for treatment. The government of Japan has also approved the use of “Remdesivir” and “steroid dexamethasone” drugs in the treatment of Kovid-19 so far. Baricitinib “pills will be used once a day and together with” Remdesivir “drug for adult patients who need supplemental…

"Approved for use against rheumatoid arthritis drug Kovid-19"

Russian vaccine Spuntik V in 10 questions: How was it developed, how many countries approved it? – Health News

The fact that the Sputnik-V vaccine will be launched after the Chinese Sinovac and the USA / German made BioNTech in Turkey turned the eyes to the Russian vaccine. The average efficiency rate of the vaccine developed in Russia was announced as 90 percent. Two doses of the vaccine, administered 42 days apart, are currently approved in 61 countries. Request Sputnik V people wondering about the vaccine … 1-HOW WAS IT DEVELOPED? According to the…

"Russian vaccine Spuntik V in 10 questions: How was it developed, how many countries approved it? – Health News"

How it was developed, how many countries have approved it: the Russian vaccine in 10 questions – health news

The fact that the Sputnik-V vaccine will be launched after the Chinese Sinovac and the USA / German made BioNTech in Turkey turned the eyes to the Russian vaccine. The average efficiency rate of the vaccine developed in Russia was announced as 90 percent. Two doses of the vaccine, administered 42 days apart, are currently approved in 61 countries. Here are those who are curious about the Sputnik V vaccine … 1-HOW WAS IT DEVELOPED?…

"How it was developed, how many countries have approved it: the Russian vaccine in 10 questions – health news"

Japan Ministry of Health expert delegation approved the drug “Baricitinib” for Covid-19 treatment – Health News

The expert delegation of the Ministry of Health, Labor and Welfare of Japan approved the use of rheumatoid arthritis drug “Baricitinib” in the treatment of the new type of corona virus (Covid-19). According to the Kyodo agency, the rheumatic arthritis drug “Baricitinib”, produced by the US Eli Lily, was approved by the expert health delegation under the ministry. The company applied to the ministry for approval of the drug in December. The ministry is expected…

"Japan Ministry of Health expert delegation approved the drug “Baricitinib” for Covid-19 treatment – Health News"

“The first domestic vaccine can be approved for emergency use in Phase-3” – Health News

Erciyes University (ERUs) Vaccine Research and Development Center on-site (I ERAG) and Good Clinical Practice and Research Center (IC I) by developed and with the Ministry of Health against coronavirus Turkey Institutes of Health Presidency (TÜSEB) Phase-1 of supported Covidien-19 domestic vaccine The study was conducted on 44 volunteers. Phase-2 study of the inactive vaccine started on 250 volunteers on 10 February and was completed on 9 March. The reporting process of the results obtained…

"“The first domestic vaccine can be approved for emergency use in Phase-3” – Health News"

The last fighter of the pandemic: Novavax Covid-19 vaccine is expected to be approved soon – Health News

HOW EFFECTIVE? In a study conducted on 15 thousand people in the UK, it was revealed that the Novavax vaccine was 89 percent effective in preventing Covid-19. In clinical trials in which more than 15 thousand people between the ages of 18-84 participated, 27 percent of whom were over the age of 65, it was stated that the vaccine provided 100 percent protection against serious diseases, including hospitalization and death. Based on the Phase 3…

"The last fighter of the pandemic: Novavax Covid-19 vaccine is expected to be approved soon – Health News"

The EU’s vaccine identity is only for approved vaccines.

Ylva Johansson, Commissioner for Internal Affairs of the European Union (EU) Commission, said in Brussels on Friday that the EU’s planned vaccine identification will only document vaccines that have been approved by the European Medicines Agency (EMA). This statement means that those who use Russian and Chinese vaccines intended to be used in some European countries will not be given a vaccine ID. In addition to the vaccine developed by EMA in partnership with Biontech…

"The EU’s vaccine identity is only for approved vaccines."